Alnylam Pharmaceuticals News

Wolfe Upgrades Ionis to Outperform, Cites Upcoming Catalysts

Seeking AlphaApr 10 12:03 ET

Alnylam Pharmaceuticals Analyst Ratings

BenzingaMar 27 10:06 ET

Alnylam Pharmaceuticals Analyst Ratings

BenzingaMar 5 12:03 ET

Alnylam Pharmaceuticals Analyst Ratings

BenzingaFeb 23 12:07 ET

Alnylam Pharmaceuticals Analyst Ratings

BenzingaFeb 21 09:51 ET

Alnylam Pharmaceuticals Analyst Ratings

BenzingaFeb 20 10:20 ET

Maintaining Hold on Alnylam Pharmaceuticals Amid Clinical and Financial Uncertainties

TipRanksFeb 18 23:55 ET

Alnylam Pharmaceuticals Analyst Ratings

BenzingaFeb 16 11:51 ET

Alnylam Pharma (ALNY) Was Downgraded to a Hold Rating at Goldman Sachs

TipRanksFeb 15 18:25 ET

Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $165 Price Target

BenzingaFeb 15 09:17 ET

Alnylam Pharmaceuticals Analyst Ratings

BenzingaFeb 13 12:30 ET

Alnylam Pharmaceuticals Analyst Ratings

BenzingaFeb 12 12:43 ET

JP Morgan Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to $170

BenzingaFeb 1 09:16 ET

Alnylam Pharmaceuticals Analyst Ratings

BenzingaFeb 1 09:15 ET

Alnylam Pharmaceuticals Analyst Ratings

BenzingaJan 22 08:43 ET

Alnylam Pharmaceuticals Analyst Ratings

BenzingaJan 18 11:16 ET

RBC Raises Price Target on Alnylam Pharmaceuticals to $235 From $230, Keeps Outperform Rating

MT NewswiresJan 3 08:00 ET

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $395 Price Target

BenzingaDec 15, 2023 13:31 ET

Alnylam Pharmaceuticals Analyst Ratings

BenzingaDec 15, 2023 13:28 ET

Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $165 Price Target

BenzingaDec 14, 2023 12:31 ET